Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab versus risedronate for pain and quality of life after osteoporotic vertebral fracture
jRCT1061230099Completed
- Start
- Feb 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of romosozumab and risedronate in osteoporosis and vertebral compression fracture (VCF) (2 arms). Primary endpoint: Weeks until NRS decreases to 4. Started Feb 2024; status: completed.
02
Drugs
romosozumabrisedronate
03
Conditions
osteoporosisvertebral compression fracture (VCF)
Beyond the preview
Go deeper on jRCT1061230099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1061230099.